Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prednisolone Addition for Patients With Recent-onset Psychotic Disorder: the Role of Immune-modulating Strategies in the Treatment of Psychosis

NCT02949232 is registered in ClinicalTrials.gov with UMC Utrecht as lead sponsor.

NCT NCT02949232
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02949232 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prednisolone Addition for Patients With Recent-onset Psychotic Disorder: the Role of Immune-modulating Strategies in the Treatment of Psychosis
Lead sponsor
UMC Utrecht
Phase
Phase 4
Overall status
Terminated
Start date
July 31, 2014
Completion date
May 31, 2019
Enrollment
42 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

psychotic disorder nos, schizoaffective disorder, schizophrenia, schizophreniform disorder